All In Biotech

Free tool

FAERS Monitor: Afinitor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022334 or its brand name (Afinitor, Everolimus). Reports on generic versions are filed under their own applications.

Reports

49,330

Serious

38,255

78% of reports

Hospitalization

14,903

Death reported

10,696

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death6,201
  • malignant neoplasm progression4,730
  • diarrhoea4,043
  • fatigue3,792
  • stomatitis3,131
  • nausea2,831
  • dyspnoea2,603
  • drug ineffective2,360
  • decreased appetite2,113
  • pyrexia2,107
  • vomiting2,091
  • rash1,985
  • weight decreased1,924
  • asthenia1,897
  • cough1,867

Reports by year received

View as table
YearReports
20042
20051
20065
200715
200834
2009188
2010928
20111,441
20122,329
20132,124
20142,289
20153,950
20164,796
20173,988
20184,749
20194,680
20204,217
20213,392
20222,678
20232,517
20242,108
20251,586
20261,313

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,829 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
stomatitisSignal3,13123.222.463,103
malignant neoplasm progressionSignal4,73020.620.084,517
decreased appetiteSignal2,1133.93.74,573
deathSignal6,2013.13.09,037
weight decreasedSignal1,9243.02.82,497
coughSignal1,8672.92.72,257
diarrhoeaSignal4,0432.72.64,367
pyrexiaSignal2,1072.62.52,106
astheniaSignal1,8972.22.11,191
fatigueSignal3,7922.12.02,202
dyspnoea2,6032.01.91,261
rash1,9851.91.9927
vomiting2,0911.91.8907
nausea2,8311.51.5533
drug ineffective2,3600.80.7185

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.